Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RARA | P10276 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.46 |
| ▸ | RARG | P13631 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 7/20 | 0.42 |
| ▸ | PRKCG | P05129 | 1/20 | 0.42 |
| ▸ | PRKCB | P05771 | 1/20 | 0.42 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6591370 | 0.90 | KMT2A (0.41) | CYP3A4KMT2ARARARARBRARG | |
| SCHEMBL6595226 | 0.88 | CYP3A4 (0.63) | CYP3A4KMT2ARARARARBRARG | |
| SCHEMBL6589030 | 0.88 | PRKCA (0.39) | CYP3A4KMT2ARARARARBRARG | |
| SCHEMBL6591091 | 0.86 | KMT2A (0.38) | CYP3A4KMT2ARARARARBRARG | |
| SCHEMBL3627617 | 0.84 | RARB (0.52) | CYP3A4RARARARBRARG | |
| SCHEMBL8558273 | 0.79 | RARA (0.56) | CYP3A4KMT2ARARARARBRARG | |
| SCHEMBL6591210 | 0.78 | ALDH1A1 (0.56) | CYP3A4KMT2ARARARARBRARG | |
| SCHEMBL9007075 | 0.77 | RARB (0.49) | CYP3A4KMT2ARARARARBRARG | |
| SCHEMBL5960214 | 0.77 | RARB (0.35) | CYP3A4KMT2ARARARARBRARG | |
| SCHEMBL8333538 | 0.75 | RARB (0.46) | CYP3A4RARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4738738-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| EP-1576089-A4 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD (IL) | 2007-02-14 | — | — | EP | claimed |
| EP-1485464-A4 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA CELL LTD (IL) | 2006-11-29 | — | — | EP | claimed |
| US-20050220774-A1 | Methods of inducing differentiation in ex vivo expanded stem cells | GAMIDA CELL LTD. (IL) | 2005-10-06 | — | — | US | claimed |
| JP-2005528088-A | — | — | 2005-09-22 | — | — | JP | claimed |
| EP-1576089-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | Gamida Cell Ltd. (IL) | 2005-09-21 | — | — | EP | claimed |
| EP-1534820-A2 | EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CULTURES | Gamida Cell Ltd. (IL) | 2005-06-01 | — | — | EP | claimed |
| US-20050008624-A1 | Expansion of renewable stem cell populations | GAMIDA CELL LTD. | 2005-01-13 | — | — | US | claimed |
| EP-1485464-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | Gamida Cell Ltd. (IL) | 2004-12-15 | — | — | EP | claimed |
| WO-2004016731-A2 | EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CULTURES | GAMIDA-CELL LTD. (IL) | 2004-02-26 | — | — | WO | claimed |
| WO-2003078567-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA-CELL LTD. (IL) | 2003-09-25 | — | — | WO | claimed |
| WO-2003062369-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA-CELL LTD. (IL) | 2003-07-31 | — | — | WO | claimed |
| EP-2026778-B1 | RAR ANTAGONIST OR INVERSE AGONIST FOR USE IN THE TREATMENT OF CHEMOTHERAPY AND/OR RADIATION THERAPY SIDE EFFECTS | IO THERAPEUTICS LLC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-20180320139-A1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL INC. | 2018-11-08 | — | — | US | disclosed |
| US-20160097037-A1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD. | 2016-04-07 | — | — | US | disclosed |
| US-9271946-B2 | Use of a RAR antagonist or inverse agonist for the treatment of chemotherapy and/or radiation therapy side effects | Io Therapeutics, Inc. (US) | 2016-03-01 | — | — | US | disclosed |
| EP-1042313-A1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST LIKE ACTIVITY | Allergan Sales, Inc. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000019990-A2 | RAR ANTAGONISTS AS MALE ANTI-FERTILITY AGENTS | ALLERGAN SALES, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
| US-5958954-A | 2,2-DIALKYL-4-ARYL-SUBSTITUTED BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES | ALLERGAN SALES, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| WO-1999033821-A1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST-LIKE ACTIVITY | ALLERGAN SALES, INC. (US) | 1999-07-08 | — | — | WO | disclosed |